Diabetes Mellitus

Pediatric Endocrinology

Volumn , Issue , 2008, Pages 374-421

  Sperling, Mark A ^a,b   Weinzimer, Stuart A ^c   Tamborlane, William V ^c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Diabetes and Endocrinol Res Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81155136988     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141604090-3.50015-6     Document Type: Chapter

References (307)

1. Ize-Ludow D, Sperling MA The classification of diabetes Mellitus: A conceptual Framework. Pediatr Clin N Am 2005, 52:1533-1552.
2. Pambianco G, Cousacou T, Ellis D, et al. The 30 year natural history of type 1 diabetes complications: The Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006, 55:1463-1469.
3. Saltiel AR, Kahn CR Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
4. Daneman D Type 1 diabetes. Lancet 2006, 367:847-858.
5. Eisenbarth GS Update in type 1 diabetes. J Clin Endocrinol Metab 2007, 92:2403-2407.
6. Hattersley A, Bruining J, Shield J, et al. ISPAD Clinical Practice Consensus Guidelines 2006-2007: The diagnosis and management of monogenic diabetes in children. Pediatric Diabetes 2006, 7:352-360.
7. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2007, 30:S42-S47.
8. Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007, 92:88-92.
9. Trucco M, Giannoukakis N Immunoregulatory dendritic cells to prevent and reverse new-onset type 1 diabetes mellitus. Expert Opin Biol Ther 2007, 7:951-963.
10. Stark R, Roden M ESCI Award 2006, Mitochondrial function and endocrine disease. Eur J Clin Invest 2007, 37:236-248.
11. Chinnery P, Howell N, Andrews R, Turnbull D Clinical mitochondrial genetics. J Med Genet 1999, 36:425-436.
12. Maassen JA, Tafrechi RS J, Raap AK, et al. New insights in the molecular pathogenesis of the maternally inherited diabetes and deafness syndrome. Endocrinol Metab Clin N Am 2006, 35:385-396.
13. Fajans SS, Bell GI, Polonsky JS Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001, 345:971-980.
14. Rosenecker J, Eichler I, Kuhn L, et al. Genetic determination of diabetes mellitus in patients with cystic fibrosis. J Pediatr 1995, 127:441-443.
15. Mackle AD, Thornton SJ, Edenborough FP Cystic fibrosis-related diabetes. Diabet Med 2003, 20:425-436.
16. Heit JJ Calcineurun/NFAT signaling in the beta cell: From diabetes to new therapeutics. Bioessays 2007, 29:1011-1021.
17. David-Neto E, Lemos FC, Fadel LM, et al. The dynamics of glucose metabolism inder calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007, 84:50-55.
18. Esposti MD, Ngo A, Myers MA Inhibition of mitrochondrial complex 1 may account for IDDM induces by intoxication with therodenticide Vacor. Diabetes 1996, 45:1531-1534.
19. Strosberg J, Hoffe S, Gardner N, et al. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 2007, 85:216-220.
20. Nesmith JD, Ellis E Childhood hemolyic uremic syndrome is associated with adolescent-onset mellitus. Pediatr Nephrol 2007, 22:294-297.
21. de Lonlay-Debeney P, Poggi-Travert F, Fournet JC, et al. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 1999, 340:1169-1175.
22. Dabelea D, Pettitt DJ, Jones KL, Arslanian SA Type 2 diabetes in minority children and adolescents. Endocrinol Metab Clin North Am 1999, 28:709-729.
23. Writing Group for the SEARCH for Diabetes in Youth Study Group, et al. Incidence of diabetes in youth in the United States. JAMA 2007, 297:2716-2724.
24. Slingerland AS Monogenic diabetes in children and young adults: Challenges for researcher, clinician and patient. Rev Endocr Metab Disord 2006, 7:171-185.
25. Santer R, Schneppenheim R, Dombrowski A, et al. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet 1997, 17:324-326.
26. Zouali H, Velho G, Frouguel P Polymorphism of the glycogen synthase gene and non-insulin dependent diabetes mellitus. N Engl J Med 1993, 328:1568.
27. Henriksen EJ, Dokken BB (year). Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 7:1435-1441.
28. Taylor SI, Cama A, Accili D, et al. Mutations in the insulin receptor gene. Endocr Rev 1992, 13:566-595.
29. Reynet C, Kahn CR Rad: A member of the Ras family overexpressed in muscle of type 2 diabetic humans. Science 1993, 262:1441-1444.
30. Polonsky KS The beta-cell in diabetes: From molecular genetics to clinical research. Diabetes 1995, 4:705-717.
31. Polonsky KS, Sturis JP, Bell GI Non-insulin-dependent diabetes mellitus: A genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996, 334:777-783.
32. Permutt MA, Chiu K, Ferrer J, et al. Genetics of type 2 diabetes. Recent Prog Horm Res 1998, 53:201-216.
33. Kahn BB Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance. Cell 1998, 92:593-596.
34. Saltiel AR New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001, 104:517-529.
35. Almind K, Doria A, Kahn CR Putting the genes for type 2 diabetes on the map. Nat Med 2001, 7:277-279.
36. Froguel P, Velho G Genetic determinants of type 2 diabetes. Recent Prog Horm Res 2001, 56:91-105.
37. Bergman RN, Ader M Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000, 11:351-356.
38. Duggirala R, Blangero J, Almasy L, et al. A major locus for fasting insulin concentrations and insulin resistance on chromosome 6q with strong pleiotropic effects on obesity-related phenotypes in nondiabetic Mexican-Americans. Am J Hum Genet 2001, 68:1149-1164.
39. Flier JS Diabetes: The missing link with obesity?. Nature 2001, 409:292-293.
40. Unger RH, Zhou YT Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001, 50(1):S118-S121.
41. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
42. Schranz DB, Bekris L, Landin-Olsson M, et al. Newly diagnosed latent autoimmune diabetes in adults (LADA) is associated with low level glutamate decarboxylase (GAD65) and IA-2 autoantibodies. Horm Metab Res 2000, 32:133-138.
43. Libman IM, Becker DJ Coexistence of type 1 and type 2 diabetes mellitus: "Double" diabetes?. Pediatr Diabetes 2003, 4:110-113.
44. Lipman TH, Jawad AF, Murphy KM, et al. Incidence of type 1 diabetes in Philadelphia is higher in black than white children from 1995 to 1999. Epidemic or misclassification?. Diabetes Care 2006, 29:2391-2395.
45. The DIAMOND Project Group Incidence and trends of Childhood type 1 diabetes worldwide 1990-1999. Diabetic Medicine 2006, 23:857-866.
46. EURODIAB Study Group Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000, 355:873-876.
47. Libman IM, LaPorte RE Changing trends in epidemiology of type 1 diabetes mellitus throughout the world: How far have we come and where do we go from here?. Pediatric Diabetes 2005, 6:119-121.
48. Soltesz G, Patterson CC, Dahlquist G, et al. Worldwide childhood type 1 diabetes incidence: What can we learn from epidemiology?. Pediatric Diabetes 2007, 8:6-14.
49. Libman IM, LaPorte RE, Becker DJ, et al. Was there an epidemic of diabetes in nonwhite adolescents in Allegheny County, Pennsylvania?. Diabetes Care 1998, 21:1278-1281.
50. Pinhas-Hamiel O, Zeitler P Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007, 369:1823-1831.
51. Hathout EH, Sharkey J, Racine M, et al. Diabetic autoimmunity in infants and pre-schoolers with type 1 diabetes. Pediatr Diabetes 2000, 1:131-134.
52. Imagawa A, Hanafusa T, Miyagawa JI, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000, 342:301-307.
53. Urakami T, Inami I, Morimoto S, et al. Clinical characteristics of non-immune-mediated, idiopathic type 1 (Type 1B) diabete mellitus in Japanese children and adolescents. J Pediatr Endocrinol Metab 2002, 15:283-288.
54. Knip M, Veijola R, Virtanen SM, et al. Enviromental triggers and determints of type 1 diabetes. Diabetes 2005, 54(2):S125-S136.
55. Menser MA, Forrest JM, Bransby RD Rubella infection and diabetes mellitus. Lancet 1978, 1:57-60.
56. Ou D, Mitchell LA, Metzger DL, et al. Cross-reactive rubella virus and glutamic acid decarboxylase (65 and 67) protein determinants recognized by T cells of patients with type 1 diabetes mellitus. Diabetologia 2000, 43:750-762.
57. Yoon JW, Austin M, Onodera T, Notkins AL Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979, 300:1173-1179.
58. The TEDDY Study Group The Environmental Determinants of Diabetes in the Young (TEDDY) study: Study design. Pediatr Diabetes 2007, 8:286-298.
59. Hiemstra HS, Schloot NC, van Veelen PA, et al. Cytomegalovirus in autoimmunity: T cell cross reactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci USA 2001, 98:3988-3991.
60. Lammi N, Karvonen M, Tuomilehto J Do microbes have a casual role in type 1 diabetes?. Med Sci Monit 2005, 11:RA63-RA69.
61. Khalil I, d'Auriol L, Gobet M, et al. A combination of HLA-DQ beta Asp57-negative and HLA-DQ alpha ARG52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest 1990, 85:1315-1319.
62. Deng GY, Muir A, Maclaren NK, She JX Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus. Am J Hum Genet 1995, 56:528-534.
63. Loew CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype association implicates polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007, 39:1074-1082.
64. Friday RP, Trucco M, Pietropaolo M Genetics of type 1 diabetes mellitus. Diabetes Nutr Metab 1999, 12:3-26.
65. Kulmala P, Rahko J, Savola K, et al. Beta-cell autoimmunity, genetic susceptibility, and progression to type 1 diabetes in unaffected schoolchildren. Diabetes Care 2001, 24:171-173.
66. Reed P, Cucca F, Jenkins S, et al. Evidence for a type 1 diabetes susceptibility locus (IDDM10) on human chromosome 10p11-q11. Hum Mol Genet 1997, 6:1011-1016.
67. Ilonen J, Reijonen H, Green A, for the Childhood Diabetes in Finland Study Group, et al. Geographical differences within Finland in the frequency of HLA-DQ genotypes associated with type 1 diabetes susceptibility. Eur J Immunogenet 2000, 27:225-230.
68. Concannon P, Erlich HA, Julier C Type 1 diabetes: Evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes 2005, 54:2995-3001.
69. Nejentsev S, Smink LJ, Smyth D, et al. Sequencing and association analysis of the type 1 diabetes-linked region on chromosome 10p12-q11. BMC Genet 2007, 8:24.
70. Payne F, Cooper JD, Walker NM, et al. Interaction analysis of the CBLB and CTLA4 genes in type 1 diabetes. J Leukoc Biol 2007, 81:581-583.
71. Taniguchi H, Lowe CE, Cooper JD, et al. Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes. BMC Genet 2006, 7:22.
72. Todd JA Statistical false positive or true disease pathway?. Nat Genet 2006, 38:731-733.
73. Dorman J, LaPorte R, Stone R, Trucco M Worldwide differences in the incidence of type 1 diabetes are associated with amino acid variation at position 57 of the HLA-DQ beta chain. Proc Natl Acad Sci USA 1990, 87:7370-7374.
74. Allen C, Palta M, D'Alessio DJ Risk of diabetes in siblings and other relatives of IDDM subjects. Diabetes 1991, 40:83-86.
75. Siljander HT, Veijola R, Reunanen A, et al. (2007). Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia (E-pub ahead of print).
76. Skyler JS Prediction and prevention of type 1 diabetes: Progress, problems and prospects. Clin Pharmacol Ther 2007, 81:768-771.
77. van der Werf N, Kroese FG, Rozing J, Hillebrands JL Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007, 23:169-183.
78. Sonderstrup G, McDevitt HO DR, DQ, and you: MHC alleles and autoimmunity. J Clin Invest 2001, 107:795-796.
79. Karjalainen J, Martin JM, Knip M, et al. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med 1992, 327:302-307.
80. Atkinson MA, Bowman MA, Kao KJ, et al. Lack of immune responsiveness to bovine serum albumin in insulin-dependent diabetes. N Engl J Med 1993, 329:1853-1858.
81. Norris JM, Beaty B, Klingensmith G, Yu Liping, the Diabetes Autoimmunity Study in the Young (DAISY), et al. Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. JAMA 1996, 276:609-614.
82. Vaarala O Is it dietary insulin?. Ann NY Acad Sci 2006, 1079:350-359.
83. Knip M Cow's milk antibodies in patients with newly diagnosed type 1 diabetes: Primary or secondary?. Pediatr Diabetes 2003, 4:155-156.
84. Tiittanen M, Paronen J, Savilahti E, Virtanen SM, et al. Dietary insulin as an immunogen and tolerogen. Pediatr Allergy Immunol 2006, 17:538-543.
85. Symon DN, Hennessy ER, Smail PJ Smoked foods in the diets of mothers of diabetic children. Lancet 1984, 2:514.
86. Hathout EH, Beeson WL, Nahab F, Rabadi A, et al. Role of exposure to air pollutants in the development of type 1 diabetes before and after 5 yr of age. Pediatr Diabetes 2002, 3:184-188.
87. Maclaren N, Lan M, Coutant R, et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2 beta predict immune-mediated (type 1) diabetes in relatives. J Autoimmun 1999, 12:279.
88. Pietropaolo M, Yu S, Libman IM, Pietroapolo SL, et al. Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies. Pediatr Diabetes 2005, 6:184-192.
89. Knip M Prediction and prevention of type 1 diabetes. Acta Paediatr Suppl 1998, 425:54.
90. Sibley RK, Sutherland DE, Goetz F, Michael AF Recurrent diabetes mellitus in the pancreas iso- and allograft: A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985, 53:132-144.
91. Pietropaolo M, Becker DJ Type 1 diabetes intervention trials. Pediatr Diabetes 2001, 2:2.
92. Lipton RB Is now the time for an intervention to prevent autoimmune type 1 diabetes?. Pediatr Diabetes 2001, 2:12.
93. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-s autoantibodies. Diabetes 1996, 45:926.
94. Wilson DM, Buckingham B Prevention of type 1a diabetes mellitus. Pediatr Diabetes 2001, 2:17.
95. Conrad B, Trucco M Superantigens as etiopathogenetic factors in the development of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1994, 10:309.
96. Keller RJ, Eisenbarth GS, Jackson RA Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993, 341:927.
97. Diabetes Prevention Trial - Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002, 346:1685-1691.
98. Gale EA Can we change the course of beta-cell destruction in type 1 diabetes?. N Engl J Med 2002, 346:1740-1742.
99. Gale EA, Bingley PJ, Emmett CL, Collier T, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomized controlled trial of intervention before the onset of type 1 diabetes. The Lancet 2004, 363:925-931.
100. Wang PH Commentary: Growing pains in the pursuit of diabetes prevention. The Lancet 2004, 363:901.
101. Barker JM, Eisenbarth GS Primary prevention of type 1A diabetes: Are we there yet?. Pediatr Diabetes 2007, 8:115-116.
102. Barker JM, McFann KK, Orban T Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 2007, 50:1603-1606.
103. The TRIGR Study Group Study design of the Trial to reduce IDDM in the Genetically at Risk (TRIGR). Pediatric Diabetes 2007, 8:117-137.
104. Gruppuso PA, Gorden P, Kahn CR, et al. Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin. N Engl J Med 1984, 311:629-634.
105. Tager HS Abnormal products of the human insulin gene. Diabetes 1984, 33:693-699.
106. O'Rahilly S, Gray H, Humphreys PJ, et al. Impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1995, 333:1386-1390.
107. Gabbay KH The insulinopathies. N Eng J Med 1980, 302:165-167.
108. Steiner DF, Tager HS, Chan SJ, et al. Lessons learned from molecular biology of insulin-gene mutations. Diabetes Care 1990, 13:600-609.
109. Steiner DF The proinsulin C-peptide: A multirole model. Exp Diabesity Res 2004, 5:7-14.
110. Steiner DF, James DE Cellular and molecular biology of the beta cell. Diabetologia 1992, 35(2):S41-S48.
111. Jackson RS, Creemers JWM, Ohagi S, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997, 16:30-63.
112. Boitard C, Efendic S, Ferrannini E, et al. A tale of two cousins: Type 2 and type 2 diabetes. Diabetes 2005, 54(2):S1-S3.
113. Wardlaw SL Obesity as a neuroendrocrine disease: Lessons to be learned from pro-opiomelanocortin and melanocortin receptor mutations in mice and men. J Clin Endocrinol Metab 2001, 86:1442-1446.
114. Nanjo K, Miyano M, Kondo M, et al. Insulin Wakayama: Familial mutant insulin syndrome in Japan. Diabetologia 1987, 30:87-92.
115. Polonsky KS, Licinio-Paixae J, Given BD, et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. J Clin Invest 1986, 77:98-105.
116. Takasawa S, Nata K, Yonekura H, et al. Cyclic ADP-ribose in insulin secretion from pancreatic beta-cells. Science 1993, 259:370-373.
117. Felig P, Wahren J, Sherwin R, et al. Insulin, glucagon, and somatostatin in normal physiology and diabetes mellitus. Diabetes 1976, 25:1091-1099.
118. Unger RH, Orci L Glucagon and the A cell: Physiology and pathophysiology. N Engl J Med 1981, 304:1575-1580.
119. Woods SC, Porte D Neural control of the endocrine pancreas. Physiol Rev 1974, 54:596-619.
120. Ashcroft FM ATP-sensitive potassium channelopathies: Focus on insulin secretion. J Clin Invest 2005, 115:2047-2058.
121. Seaquist ER, Walseth TF, Redmon JB G protein regulation of insulin secretion. J Lab Clin Med 1994, 123:338-345.
122. Wallace TM, Matthews DR Assessment of the effects of insulin secretagogues in humans. Diabetes Obes Metab 2000, 2:271-283.
123. McClenaghan NH, Flatt PR Physiological and pharmacological regulation of insulin release: Insights offered through exploitation of insulin-secreting cell lines. Diabetes Obes Metab 1999, 1:137-150.
124. Aguilar-Bryan L, Nichols CB, Wechsler SW Cloning of the beta cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 1995, 268:423-426.
125. 1 channels. Science 1995, 268:372-373.
126. Thomas PM, Cote GJ, Wohlik N, et al. Mutations in the sulfo-nylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995, 268:426-429.
127. Liang Y, Matschinsky FM Mechanisms of action of nonglucose insulin secretagogues. Annu Rev Nutr 1994, 14:59-81.
128. Drucker DJ, Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
129. Amori RE, Lau J, Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007, 298:194-205.
130. Porte A, Baskin DG, Schwartz MW Insulin signaling in the central nervous system: A critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005, 54:1264-1276.
131. Cheatham B, Kahn CR Insulin action and the insulin signaling network. Endocr Rev 1995, 16:117-142.
132. Kido Y, Nakae J, Accili D Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001, 86:972-979.
133. Bevan P Insulin signaling. J Cell Sci 2001, 114:1429-1430.
134. Taniguchi CM, Emanuelli B, Kahn CR Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Bio 2006, 7:85-96.
135. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000, 289:2122-2125.
136. Biddinger SB, Kahn CR From mice to men: Insights into the insulin resistance syndromes. Annu Rev Physiol 2006, 68:123-158.
137. Brady MJ, Saltiel AR The role of protein phosphatase-1 in insulin action. Recent Prog Horm Res 2001, 56:157-173.
138. Chang L, Chiang SH, Saltiel AR Insulin signaling and the regulation of glucose transport. Mol Med 2004, 10:65-71.
139. Rizza RA, Mandarino LJ, Gerich JE Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 1981, 240:E630-E639.
140. Schade DS, Eaton RP The temporal relationship between endogenously secreted stress hormones and metabolic decompensation in diabetic man. J Clin Endocrinol Metab 1980, 50:131-136.
141. Wolfsdorf J, Glaser N, Sperling M, the American Diabetes Association Diabetes Ketoacidosis in infants, children and adolescents: A consenus statement from the American Diabetes Association. Diabetes Care 2006, 29:1150-1159.
142. Wolfsdorf J, Craig ME, Daneman D, et al. Diabetes ketoacidosis. Pediatr Diabetes 2007, 8:28-43.
143. Foster DW, McGarry JD The metabolic derangements and treatment of diabetic ketoacidosis. N Engl J Med 1983, 309:159-169.
144. Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med 2001, 344:264-269.
145. Glaser N New perspectives on the pathogenesis of cerebral edema complicating diabetic ketoacidosis in children. Pediatr Endocrinol Rev 2006, 3:379-386.
146. Sperling MA Cerebral edema in diabetes ketoacidosis: An underestimated complication?. Pediatr Diabetes 2006, 7:73-74.
147. Cody D Infant and toddler diabetes. Arch Dis Child 2007, 92:716-719.
148. Rosenbloom AL Hyperglycemic comas in children: New insights into pathophysiology and management. Rev Endocr Metab Disord 2005, 6:297-306.
149. Fourtner SH, Weinzimer SA, Levitt Katz LE Hyperglycemic hyperosmolar non-ketotic syndrome in children with type 2 diabetes. Pediatr Diabetes 2005, 6:129-135.
150. Rosenbloom AL Hyperglycemia crises and their complications in children. J Pediatr Endocrinol Metab 2007, 20:5-18.
151. Adrogue HJ, Wilson H, Boyd AE, et al. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982, 307:1603-1610.
152. Arieff AI Pathogenesis of lactic acidosis. Diabetes Metab Rev 1989, 5:637-649.
153. Assadi FK, John EG, Fornell MT, et al. Falsely elevated serum creatinine concentration in ketoacidosis. J Pediatr 1982, 107:562-564.
154. White NH Diabetic ketoacidosis in children. Endocrinol Metab Clin North Am 2000, 29:657-682.
155. Halperin ML, Maccari C, Kamel KS, et al. Strategies to diminish the danger of cerebral edema in a pediatric patient presenting with diabetes ketoacidosis. Pediatr Diabetes 2006, 7:191-195.
156. Hoorn EJ, Carlotti AP, Costa LA, et al. Preventing a drop in effective plasma osmolality to minmize the likelihood of cerebral edema during treatment of children with diabetes ketoacidosis. J Pediatr 2007, 150:467-473.
157. Rosenbloom AL Intracerebral crisis during treatment of diabetic ketoacidosis. Diabetes Care 1990, 13:22-33.
158. Bello FA, Sotos JF Cerebral edema in diabetic ketoacidosis in children. Lancet 1990, 336:64.
159. Carlotti AP, Bohn D, Jankiewicz N, et al. A hyperglycaemic hyperosmolar state in a young child: Diagnostic insights from a quantitative analysis. QJM 2007, 100:125-137.
160. Muir AB, Quisling RG, Yang MC, et al. Cerebral edema in childhood diabetis ketoacidosis: Natural history, radiographic findings and early identification. Diabetes Care 2004, 27:1541-1546.
161. Krane EJ, Rockoff MA, Wallman JK, et al. Subclinical brain swelling in children during treatment of diabetic ketoacidosis. N Engl J Med 1985, 312:1147.
162. Rosenbloom AL, Finberg L, Muir A Cerebral edema in diabetic ketoacidosis. J Clin Endocrinol Metab 2000, 85:507-513.
163. Clements RS, Blumenthal SA, Morrison AD, Winegrad AI Increased cerebrospinal-fluid pressure during treatment of diabetic ketosis. Lancet 1971, 2:671-675.
164. Winter RJ, Harris CJ, Phillips LS, et al. Diabetic ketoacidosis: Induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am J Med 1979, 67:897-900.
165. Dunger DB, Sperling MA, Acerini CL, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004, 89:188-194.
166. Latif KA, Freire AX, Kitabchi AE, et al. The use of alkali therapy in severe diabetic ketoacidosis. Diabetes Care 2002, 25:2113-2114.
167. Schade DS, Eaton RP Dose response to insulin in man: Differential effects on glucose and ketone body regulation. J Clin Endocrinol Metab 1977, 44:1038-1053.
168. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
169. Diabetes Control and Complications Trial Research Group Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994, 125:177-188.
170. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001, 139:804-812.
171. Springer D, Dziura J, Tamborlane WV, Steffen AT, Ahern JH, Vincent M, et al. Optimal control of type 1 diabetes in youth receiving intensive treatment. J Pediatr 2006, 149:227-232.
172. Grey M, Boland EA, Davidson M, Li J, Tamborlane WV Coping skills training for youth on intensive therapy has long lasting effects on metabolic control and quality of life. J Pediatr 2000, 137:107-114.
173. Tamborlane WV, Bonfig W, Boland E Recent advances in the treatment of youth with type 1 diabetes: Better care through technology. Diabetic Medicine 2001, 18:864-870.
174. Andersen JH, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R, the Multicenter Insulin Lispro Study Group Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997, 19:62-71.
175. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T Insulin lispro in CSII, results of a double-blind study. Diabetes 1997, 46:440-443.
176. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000, 23:583-588.
177. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR [Lys(B28), Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin. Diabetes 1994, 43:396-402.
178. Vajo Z, Fawcett J, Duckworth WC Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocr Rev 2001, 22:706-717.
179. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004, 53:1614-1620.
180. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142-2148.
181. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K, the Pediatric Study Group of Insulin Glargine Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15:369-376.
182. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003, 26:799-804.
183. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007, 30:2447-2452.
184. Tamborlane WV, Sherwin RS, Genel M, Felig P Reduction to normal of plasma glucose in juvenile diabetics by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979, 300:573-578.
185. Pickup JC, Keen H, Parsons JA, Alberti KG Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. Br Med J 1978, 1:204-207.
186. Weinzimer S, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica 2004, 95:85-92.
187. Sikes KA, Ahern J, Weinzimer SA, Tamborlane WV Practical aspects of insulin pump therapy in children with diabetes mellitus: The Yale experience. Infusystems USA 2005, 4:25-28.
188. Boland EA, Grey M, Fredrickson L, Tamborlane WV CSII: A "new" way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type I diabetes. Diabetes Care 1999, 22:1779-1894.
189. Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, et al. Insulin pump therapy in pediatrics: A therapeutic alternative to safely lower therapy HbA1c levels across all age groups. Pediatric Diabetes 2002, 3:10-15.
190. Weinzimer SA, Ahern JH, Doyle EA, Dzuria J, Steffen AL, Tamborlane WV Persistence of benefits of continuous subcutaneous insulin infusion (CSII) in very young children with type 1 diabetes mellitus. Pediatrics 2004, 114:1601-1605.
191. Attia N, Jones TW, Holcombe J, Tamborlane WV Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998, 21:817-821.
192. Doyle EA, Weinzimer SA, Steffen AL, Ahern JH, Vincent M, Tamborlane WV A randomized, prospective trial comparing continuous subcutaneous insulin infusion and with multiple daily injections using insulin glargine in youth with type 1 diabetes mellitus. Diabetes Care 2004, 27:1554-1558.
193. Weinzimer SA, Tamborlane WV Diabetes mellitus in children and adolescents. Clinical diabetes 2006, 505-521. Saunders Elsevier, [city]. V. Fonseca (Ed.).
194. Edge JA, Matthews DR, Dunger DB The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol 1990, 33:729-737.
195. Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003, 143:737-740.
196. Kaplan W, Rodriguez LM, Smith OE, Haymond MW, Heptulla RA Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care 2004, 27:2739-2740.
197. The Diabetes Research in Children Network Study Group Accuracy of newer generation home blood glucose meters in a Diabetes Research in Children Network (DirecNet) inpatient exercise study. Diabetes Technol Ther 2005, 7:675-680.
198. Bina DM, Anderson RL, Johnson ML, Bergenstal RM, Kendall DM Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Diabetes Care 2003, 26:981-985.
199. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV Impaired insulin action in puberty: A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986, 315:215-219.
200. Weinzimer S, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica 2004, 95:85-92.
201. The Diabetes Research in Children Network Study Group A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with type 1 diabetes. Diabetes Care 2005, 1101-1106.
202. Weinzimer S, Tamborlane WV, Chase HP, Garg SK Continuous glucose monitoring and new insulin regimens in type 1 diabetes. Current Diabetes Reports 2004, 4:95-100.
203. Boland EA, DeLucia M, Brandt C, Grey MJ, Tamborlane WV Limitations of conventional methods of self blood glucose monitoring: Lessons learned from three days of continuous glucose monitoring in pediatric patients
204. The Diabetes Research in Children Network Study Group Positive impact of FreeStyle Navigator continuous glucose sensor use in children with type 1 DM. J Pediatr 2007, 151:388-393.
205. The Diabetes Research in Children Network Study Group The accuracy of the Freestyle Navigator continuous glucose sensor in the inpatient and outpatient setting in children with type 1 diabetes. Diabetes Care 2007, 30:59-64.
206. Tamborlane WV Fulfilling the promise of insulin pump treatment in childhood diabetes. Pediatric Diabetes 2006, 7(4):4-10.
207. Rewers A, McFann K, Chase HP Bedside monitoring of blood beta-hydroxybutyrate levels in the management of diabetic ketoacidosis in children. Diabetes Technol & Ther 2006, 8:671-676.
208. Gregory RP, Davis DL Use of carbohydrate counting for meal planning in type 1 diabetes. Diabetes Educator 1994, 20:406.
209. Aslander-van Vliet, Smart C, Waldron S Nutrition management of childhood and adolescent diabetes. Pediatric Diabetes 2007, 8:323-339.
210. American Diabetes Association Task Force for Writing Nutrition Principles, Recommendations for the Management of Diabetes and Related Complications American Diabetes Association position statement: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Amer Diet Assoc 2002, 102:109.
211. Sandoval DA, Guy DLA, Richardson MA, Ertl AC, Davis SN Effects of low and moderate exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes. Diabetes 2004, 53:1798-1806.
212. The Diabetes Research in Children Network Study Group Impact of exercise on overnight glycemic control in children with type 1 diabetes. J Pediatr 2005, 147:528-534.
213. McMahon SK, Ferreira LD, Davey RJ, Youngs LM, Davis EA, Fournier PA, et al. Glucose requirements to maintain euglycemia following moderate intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J Clin Endocrinol Metab 2007, 92:963-968.
214. Tamborlane WV Triple jeopardy for hypoglycemia on nights following exercise in youth with type 1 diabetes. J Clin Endocrinol Metab 2007, 92:815-816.
215. The DCCT Research Group Effects of age, duration and treatment of IDDM on residual ß-cell function: A study of the DCCT population. J Clin Endocrinol Metab 1987, 65:30-36.
216. The DCCT Research Group The effect of intensive diabetes treatment in the DCCT on residual insulin secretion in IDDM. Ann Int Med 1998, 28:517-523.
217. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698.
218. American Diabetes Association Workgroup on Hypoglycemia Defining and reporting hypoglycemia in Diabetes. Diabetes Care 2005, 28:1245-1249.
219. Jones TW, Boulware SD, Kraemer DT, Caprio S, Sherwin RS, Tamborlane WV Independent effects of youth and poor diabetes control on responses to hypoglycemia in children. Diabetes 1991, 40:358-363.
220. Ryan C, Gurtunca N, Becker D Hypoglycemia: A complication of diabetes therapy in children. Pediatr Clin N Am 2005, 52:1705-1733.
221. Cryer PE Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 2005, 54:3592-3601.
222. Cryer PE Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2004, 350:2272-2279.
223. Jones TW, Porter P, Sherwin RS, Davis EA, O'Leary P, Frazer F, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998, 338:1657-1662.
224. Kordonouri O, Klinghammer A, Lang EB, et al. Thyroid autoimmunity in children and adolescents with type 1 diabetes. Diabetes Care 2002, 25:1346-1350.
225. Freemark M, Levitsky LL Screening for celiac disease in children with type 1 diabetes: Two views of the controversy. Diabetes Care 2003, 26:1932-1939.
226. Delamater AM Psychological care of children and adolescents with diabetes: ISPAD Clinical Practice Consensus Guidelines 2006-2007. Pediatric Diabetes 2007, 8:340-348.
227. Kovacs M, Kass RE, Schnell TM, et al. Family functioning and metabolic control of school-aged children with IDDM. Diabetes Care 1989, 12:409.
228. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Deeb L, et al. Care of children and adolescents with type 1 diabetes: A statement of the American Diabetes Association. Diabetes Care 2005, 28:186-212.
229. Griffin ME, Feder A, Tamborlane WV Lipoatrophy associated with lispro insulin in insulin pump therapy: An old complication, a new cause?. Diabetes Care 2001, 24:174.
230. The Diabetes Research in Children Network Study Group Comparison of A1c levels assayed by the DCA 2000 and the DCCT/EDIC Central Laboratory: A Diabetes Research in Children Network study. Pediatric Diabetes 2005, 6:13-16.
231. Update on the 1987 task force report on high blood pressure in children and adolescents: A working group report for the national high blood pressure education program. Pediatrics 1996, 98:649-657.
232. Huo B, Steffen AT, Swan K, Sikes K, Weinzimer SA, Tamborlane WV Clinical outcomes and cost-effectiveness of retinopathy screening in youth with type 1 diabetes mellitus. Diabetes Care 2007, 30:362-363.
233. Rhodes ET, Ferrari LR, Wolsdorf JI Perioperative management of pediatric surgical patients with diabetes mellitus. Anesth Analg 2005, 101:986-999.
234. Betts P, Brink SJ, Swift PGF, Silink M, Wolfsdorf J, Hanas R Management of children with diabetes requiring surgery. Pediatric Diabetes 2007, 8:242-247.
235. Iserman B, Ritzel R, Zorn M, et al. Autoantibodies in diabetes mellitus: Current utility and perspectives. Exp Clin Endocrinol Diabetes 2007, 115:483-490.
236. Barrett TG Differential diagnosis of type 1 diabetes: Which genetic syndrome need to be considered?. Pediatric Diabetes 2007, 8:15-23.
237. Libman IM, Arslanian SA Prevention and treatment of type 2 diabetes in youth. Horm Res 2007, 67:22-24.
238. Gungor N, Hannon T, Libman, et al. Type 2 diabetes mellitus in youth: The complete picture to date. Pediatr Clin A Am 2005, 1579-1609.
239. Weiss R, Caprio S Altered glucose metabolism in obese youth. Pediatr Endocrinol Rev 2006, 3:233-238.
240. Savoye M, Shaw M, Dziura J, et al. Effects of a weight management program on body composition and metabolic parameters in overweight children: A randomized controlled trial. JAMA 2007, 297:2697-2704.
241. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004, 350:2362-2374.
242. Weiss R, Caprio, Trombetta, et al. Beta-cell function across the spectrum of glucose tolerance in obese youth. Diabetes 2005, 54:1735-1743.
243. Kralisch S, Sommer G, Deckert CM, et al. Adipokines in diabetes and cardiovascular diseases. Minerva Endocrinol 2007, 32:161-171.
244. Owen KR, McCarthy MI Genetics of type 2 diabetes. Curr Opin Genet Dev 2007, 17:239-244.
245. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
246. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316:1336-1341.
247. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility varients. Science 2007, 316:1341-1345.
248. Pinhas-Hamiel O, Standiford D, Hamiel D, et al. A setting for development and treatment of adolescent type 2 diabetes mellitus. Arch Pediatr Adolesc Med 1999, 153:1063-1067.
249. Rosenbloom AL Distinguishing type 1 and type 2 diabetes at diagnosis: What is the problem?. Pediatr Diabetes 2007, 8:51-52.
250. Frayling TM Genome-wide assoication studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 2007, 8:657-662.
251. Hattersley AT Prime suspect: the TCF7L2 gene and type 2 diabetes risk. J Clin Invest 2007, 117:2077-2079.
252. Salonen JT, Uimari P, Aalto JM, et al. Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium. Am J Hum Genet 2007, 81:338-345.
253. Solomon DH, Winkelmayer WC Cardiovascular risk and the thiazoiidinediones: Deja vu all over again?. JAMA 2007, 98:1216-1218.
254. Hattersley AT, Pearson ER Pharmacogenetics and beyond: The interaction of therapeutic response, beta-cell physiology, and genetics in diabetes. Endocrinology 2006, 147:2657-2663.
255. Berry GT, Baynes JW, Wells-Knecht KJ, et al. Elements of diabetec nephropathy in a patient with GLUT 2 deficiency. Mol Genet Metab 2005, 4:473-477.
256. Macaulay K, Dobie BW, Patel S, et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab 2007, 6:329-337.
257. Whittaker RG, Schaeffer AM, McFarland R, et al. Diabetes and deafness: Is it sufficient to screen foe the mitochondrial 3243A.G mutation alone?. Diabetes Care 2007, 30:2238-2239.
258. Mancuso M, Filosto M, Choub A, et al. Mtochondrial DNA-related disorders. Biosci Rep 2007, 27:31-37.
259. Khanim F, Kirk J, Latif F, et al. WFS1/wolframin mutations, Wolfram syndrome, and associated diseases. Hum Mutat 2001, 17:357-367.
260. Barrett TG, Scott-Brown M, Seller A, et al. The mitochondrial genome in Wolfram syndrome. J Med Genet 2000, 37:463-466.
261. Labay V, Raz T, Baron D, et al. Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 1999, 22:300-304.
262. Olsen BS, Hahnemann JM, Schwartz M, et al. Thiamine-responsive megalobastic anaemia: A cause of syndromic diabetes in childhood. Pediatr Diabetes 2007, 8:239-241.
263. Ferner RE Drug-induced diabetes. Baillieres Clin Endocrinol Metab 2006, 6:849-866.
264. Penfornis A, Kury-Pauliln S Immonosuppressive drug-induced diabetes. Diabetes Metab 2006, 32:539-546.
265. Dufresne RL Weighing in: Emergent diabetes mellitus and second-generation antipsychotis. Ann Pharmacother 2007, 41:1725-1727.
266. Costa M, Potvin S, Bethiaume Y, et al. Diabetes: A major co-morbidity of cystic fibrosis. Diabetes Metab 2005, 31:221-232.
267. Teinturier C, Tournade MF, Caillat-Zucman S, et al. Diabetes mellitus after abdominal radiation therapy. Lancet 1995, 346:633-634.
268. Jun HS, Yoon JW A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev 2003, 19:8-31.
269. Andreoli S, Bergstein J Exocrine and endocrine pancreatic insufficiency and calcinosis after hemolytic uremic syndrome. J Pediatr 1987, 110:816-817.
270. Low L, Chernausek SD, Sperling MA Acromegaloid patients with type A insulin resistance: Parallel defects in insulin and insulin-like growth factor-1 receptors and biological responses in cultured fibroblasts. J Clin Endocrinol Metab 1989, 69:329-337.
271. Flier JS, Moller, Moses AC, et al. Insulin-mediated pseudoacromegaly: Clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinal Metab 1993, 76:1533-1541.
272. Chernausek SD Mendelian genetic causes of the short child born small for gestational age. J Endocrinol Invest 2006, 29:16-20.
273. Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): A 30-year prospective. Medicine (Baltimore) 2004, 83:209-222.
274. Hegele RA, Joy TR, Al-Attar SA, et al. Lipodystrophies: Windows on adipose biology and metabolism. J Lipid Res 2007, 48:1433-1444.
275. Agrwal AK, Garg A Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med 2006, 57:297-311.
276. Flier JS, Kahn CR, Roth J Receptors, antireceptor antibodies and mechanisms of insulin resistance. N Engl J Med 1979, 300:413-419.
277. Crino A, DiGiorgio G, Manco M, et al. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome. Horm Res 2007, 68:83-90.
278. Gillespie KM, Dix RJ, Williams AJ, et al. Islet autoimmunity in children with Down's syndrome. Diabetes 2006, 55:3185-3188.
279. Bakalov VK, Cooley MM, Quon MJ, et al. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab 2004, 89:3516-3520.
280. Aoki N Klinefelter's syndrome, autoimmunity and associated endocrinopathies. Intern Med 1999, 38:838-839.
281. Minton JA, Owen KR, Ricketts CJ, et al. Syndromic obesity and diabetes: Changes in body composition wih age and mutation analysis if ALMS1 in 12 United Kingdom kindreds with Alstrom syndrome. J Clin Endocrinol Metab 2006, 91:3110-3116.
282. Benzinou M, Walley A, Lobbens S, et al. Bardet-Biedl syndrome gene variants are associated with both childhood and adult common obesity in French Caucasians. Diabetes 2006, 55:2876-2882.
283. Buchanan TA, Xiang AH Gestational diabetes mellitus. J Clin Invest 2005, 115:485-491.
284. Sperling MA ATP-sensitive potassium channels-neonatal diabetes mellitus and beyond. N Engl J Med 2006, 355:507-510.
285. Sperling MA The genetic basis of neonatal diabetes mellitus. Pediatr Endocrinol Rev 2006, 4:71-75.
286. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Eng J Med 2004, 350:1838-1849.
287. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonyurease in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006, 355:467-477.
288. Babenko AP, Polak M, Cave H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006, 355:456-466.
289. Hattersley AT, Ashcroft FM Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights and new therapy. Diabetes 2005, 54:2503-2513.
290. Ellard S, Flanagan Se, Girard CA, et al. Permanent neonatal diabetes caused by dominant, recessive or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 2007, 81:375-382.
291. Nakhla M, Polychronakos C Monogenic and other unusual causes of diabetes mellitus. Pediatr Clin North Am 2005, 52:1637-1650.
292. Olinder AL, Kernell A, Smide B Treatment with CSII in two infants with neonatal diabetes mellitus. Pediatr Diabetes 2006, 7:284-288.
293. Hermann R, Laine AP, Johansson C, et al. Transient but not permanent neonatal diabetes mellitus is associated with paternal uniparental isodisomy of chromosome 6. Pediatrics 2000, 105:49-52.
294. Varrault A, Bilanges B, Mackay DJ, et al. Characterization of the methlaton-sensitive promoter of the imprinted zac gene supports its role in transient neonatal diabetes mellitus. J Biol Chem 2001, 276:18653-18656.
295. Hattersley AT Unlocking the secrets of the pancreatic beta cell: Man and mouse provide the key. J Clin Invest 2004, 114:314-316.
296. Verwest AM, Poelman M, Dinjens WN, et al. Absence of a PDX-1 mutation and normal gastroduodenal immunohistology in a child with pancreatic agenesis. Virchows Arch 2000, 437:680-684.
297. Hani EH, Stoffers DA, Chevre JC, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999, 104:R41-R48.
298. Njolstad PR, Sovik O, Cuesta-Munoz A, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001, 344:1588-1592.
299. Thornton CM, Carson DJ, Stewart FJ Autopsy findings in the Wolcott-Rallison syndrome. Pediatr Pathol Lab Med 1997, 17:487-496.
300. Zhang W, Feng D, Li Y, et al. PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metab 2006, 4:491-497.
301. Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents: An IDF consensus report. Pediatr Diabetes 2007, 8:299-306.
302. Robertson RP, Davis C, Larsen J, et al. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care 2006, 29:935.
303. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Eng J Med 2006, 355:1318-1330.
304. Haddad EM, McAllister VC, Renouf E, et al. (year). Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev Oct 18:CD005161.
305. Beck J, Angus R, Madsen B, et al. Islet encapsulation: strategies to enhance islet cell functions. Tissue Eng 2007, 13:589-599.
306. Trucco M Regeneration of the pancreatic beta cell. J Clin Invest 2005, 115:5-12.
307. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297:1568-1576.